BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)
Status:
Completed
Trial end date:
2021-01-05
Target enrollment:
Participant gender:
Summary
This is an open-label, placebo run-in study to investigate the genetic and biomedical
predictors of blood pressure response to bisoprolol. After informed consent is obtained,
subjects will be withdrawn from previous antihypertensive therapy and given placebo for at
least 2 weeks. Compliance will be assessed using pill counting, and any subject will a
compliance less than 80% during the placebo run-in period will be excluded from the study.
Bisoprolol 2.5 mg will be given once daily for 6 weeks. At baseline and after 6 weeks on
bisoprolol 2.5 mg the clinic sitting blood pressure, 24-hour ambulatory blood pressure (if
the patient is willing to do this), clinical characteristics and biochemical profile will be
measured. Central aortic blood pressure will be measured with the A-PULSE device at baseline
and after 6 weeks treatment.
After completing 6 weeks treatment with bisoprolol 2.5 mg daily, the patient will continue
treatment with bisoprolol for a total of 24 weeks unless there is any adverse event that
requires discontinuation of bisoprolol.